Zobrazeno 1 - 10
of 10
pro vyhledávání: '"J Thaddeus Beck"'
Autor:
Maen A. Hussein, Raid Aljumaily, Shannon R. Morris, Bojan Zaric, Wahid Hanna, Didier Verhoeven, Z. Andric, Jie Xiao, J. Thaddeus Beck, Janakiraman Subramanian, Renata Ferrarotto, Joyce M Antal, Davorin Radosavljevic, Lowell L. Hart, Taofeek K. Owonikoko
Publikováno v:
Advances in therapy
Advances in Therapy
Advances in Therapy
Introduction Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current therapies are lineage specific and administered after chemotherapy damage has occurred. Tril
Autor:
Karen Kelly, J. Thaddeus Beck, Manish R. Patel, Hans Juergen Grote, Jaspreet Grewal, Anja von Heydebreck, Michael S. Gordon, Vikram Chand, Christina M. Annunziata, Matthew H. Taylor, Erika Hamilton, Haeseong Park, Mary L. Disis, Jorge Chaves, James L. Gulley, Kathleen M. Moore, Alain C. Mita
Publikováno v:
JAMA oncology. 5(3)
Importance Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. Objective To assess the efficacy and safety of avelumab, an anti
Autor:
Weijiang Zhang, Christine McIntyre, Stjepko Pleština, J. Thaddeus Beck, Enric Bertran, Rabab Gaafar, Hanaa M.A. Kohail, Harper Forbes, Todd Riehl
Vemurafenib prolongs survival in patients with BRAFV600 -mutated advanced melanoma. In vitro studies show cytochrome P450 (CYP) 3A4 is involved in vemurafenib metabolism, but the effect of strong inducers or inhibitors of CYP3A4 on vemurafenib exposu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3dd281933c6918c3b94a3812fa26db7
https://doi.org/10.1002/cpdd.643
https://doi.org/10.1002/cpdd.643
Autor:
J. Thaddeus Beck, Lasika Seneviratne, Robert William Sweetman, John A. Glaspy, Navneet Dhillon, Chaitali Singh Nangia, Leon Christopher Hwang, Mark S. Chambers, Jennifer K. Litton, J. Randy Sabo, Hope S. Rugo, Timothy F. Meiller, Timothy J. Pluard, Julio A Peguero, Ingrid A. Mayer
Publikováno v:
The Lancet. Oncology. 18(5)
Summary Background Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and
Autor:
Kenneth M. Attie, Elizabeth R. Plimack, Rupal S. Bhatt, Brian I. Rini, Robert S. Alter, J. Thaddeus Beck, Shuchi Sumant Pandya, Matthew L. Sherman, Dawn Wilson, Musa Mutyaba, Xiaosha Zhang, Martin H. Voss, Michael B. Atkins, Chad E. Glasser
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(14)
Purpose: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis. Concurrent targeting of ALK1 and VEGF signaling results in augmented inhibition of tumor growth in renal cell carcinoma (RCC) xenograft models. Dalantercept is an ALK1-
Autor:
Zhao Yang, Rajesh K. Malik, Janakiraman Subramanian, Lowell L. Hart, Raid Aljumaily, David R. Spigel, Renata Ferrarotto, Misha L. Johnson, Wahid Hanna, Dragana Jovanovic, Z. Andric, Maen A. Hussein, Taofeek K. Owonikoko, Bojan Zaric, Krishna Kishore Pachipala, J. Thaddeus Beck, Shannon R. Morris, Steven Adler, Miroslav Samarzija, Davorin Radosavljevic
Publikováno v:
Journal of Clinical Oncology. 37:8505-8505
8505 Background: Multi-lineage myelosuppression is an acute toxicity of cytotoxic chemotherapy leading to hematologic adverse events and dose reductions and delays. Current therapies are lineage specific and administered after chemotherapy damage.Tri
Autor:
Rafael López, Shu Fang Hsu Schmitz, Caroline Lefebvre, Soo-Chin Lee, Anne C Armstrong, Emilio Alba, Mario Campone, Mikhail Akimov, Samreen Ahmed, Massimo Aglietta, J. Thaddeus Beck, Laura Biganzoli, Anthony Kong, Daniel Rea
Publikováno v:
Oncotarget
This open-label, multicenter, phase 1B/2 trial assessed AUY922 plus trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer previously treated with chemotherapy and anti-HER2 therapy. This study was composed of a dose-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c75ef3288e9c82e851ab9d792d9c9e28
http://hdl.handle.net/2318/1579732
http://hdl.handle.net/2318/1579732
Autor:
H. Michael Shepard, William P. Harris, Sergei Tjulandin, Eduard M. Pshevlotsky, Craig Devoe, Oleg Gladkov, Ronald L. Korn, Randall F. Holcombe, Natarajan Raghunand, J. Thaddeus Beck, Boris A. Berdov, Ping Jiang, Stephanie Ann Wagner, Samuel S. Dychter, Sunil R. Hingorani
Publikováno v:
Clin Cancer Res
Purpose: This phase Ib study evaluated the safety and tolerability of PEGylated human recombinant hyaluronidase (PEGPH20) in combination with gemcitabine (Gem), and established a phase II dose for patients with untreated stage IV metastatic pancreati
Autor:
Alain C. Mita, Albert C. Lockhart, Kevin M. Chin, James L. Gulley, Anja von Heydebreck, J. Thaddeus Beck, Erika Hamilton, Shubham Pant, Michael S. Gordon, Mary L. Disis, Manish R. Patel, Karen Kelly, Matthew H. Taylor, Jean-Marie Cuillerot, Jorge Chaves, Glen J. Weiss
Publikováno v:
Journal of Clinical Oncology. 34:5533-5533
5533Background: Avelumab* is a fully human anti-PD-L1 IgG1 antibody under clinical investigation in multiple cancers. We report safety and clinical activity of avelumab in patients (pts) with recurrent/refractory ovarian cancer (OC; NCT01772004). Met
Autor:
Todd M. Bauer, Das Purkayastha, Lee S. Schwartzberg, Sebastian Szpakowski, Linda Karpiak, Daniel L. Spitz, Fadi Braiteh, Funda Meric-Bernstam, J. Thaddeus Beck, Sarina Anne Piha-Paul, Matthew H. Taylor
Publikováno v:
Scopus-Elsevier
Oncotarget
Oncotarget
Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation plays a key role in tumorigenesis and has been associated with poor prognosis and resistance to multiple therapies in various cancers. Results: There were 146 patients enrolled; comm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fda60e830e35ada2739915865aaf318
http://www.scopus.com/inward/record.url?eid=2-s2.0-85075549908&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-85075549908&partnerID=MN8TOARS